An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients

Schizophrenia Research

Volumn 100, Issue 1-3, 2008, Pages 86-96

  Abrams, Daniel J ^a   Zheng, Lijun ^a   Choo, Kevin S ^a   Yang, Jun J ^a   Wei, Wei ^c   Anchordoquy, Thomas J ^a   Zawia, Nasser H ^c   Stevens, Karen E ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Auditory gating; DBA 2 mice; Elevated plus maze; Intracerebroventricular; Open field maze; Rats

Indexed keywords

CLOZAPINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DATA ANALYSIS; DRUG FORMULATION; DRUG INFUSION; DRUG SOLUBILITY; EVOKED AUDITORY RESPONSE; MALE; MAZE TEST; MOUSE; NEUROTOXICITY; NONHUMAN; OPEN FIELD TEST; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ACOUSTIC STIMULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BETA-CYCLODEXTRINS; CELL SURVIVAL; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CLOZAPINE; DISEASE MODELS, ANIMAL; DRUG DESIGN; EVOKED POTENTIALS, AUDITORY; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MICE; MICE, INBRED DBA; NEUROTOXICITY SYNDROMES; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STARTLE REACTION;

EID: 39949085059     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.10.012     Document Type: Article

References (46)

1. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., and Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 24 2 (1998) 189-202
2. Alvir J.M., Lieberman J.A., Saffermanm A.Z., Schwimmer J.L., and Schaaf J.A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 329 3 (1993) 162-167
3. Atkin K., Kendall F., Gould D., Freeman H., Liberman J., and O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br. J. Psychiatry 169 4 (1996) 483-488
4. Azorin J.M., Spiegel R., Remington G., Vanelle J.M., Pere J.J., Giguere M., and Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am. J. Psychiatry 158 8 (2001) 1305-1313
5. Ballantyne J.C., and Carwood C.M. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst. Rev. 25 1 (2005) CD005178
6. Brambilla P., Barale F., Caverzasi E., Tognoni T., and Barui C. Clozapine-treated subjects with treatment-resistant schizophrenia: a systemic review of experimental and observational studies. Int. Clin. Psychopharmacol. 17 4 (2002) 189-195
7. Brier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., and Carpenter W.T. Effects of clozapine in schizophrenic outpatients: effects on positive and negative symptoms. Arch. Gen. Psychiatry 151 1 (1994) 20-26
8. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., and Carpenter Jr. W.T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 155 6 (1998) 751-760
9. Claghorn J., Honigfeld G., Abuzzahab F.S., Wang R., Steinbook R., Tuason V., and Klerman G. The risks and benefits of clozapine versus chlorpromazine. J. Clin. Psychopharmacol. 7 6 (1987) 377-384
10. Croft R.J., Lee A., Bertolot J., and Gruzelier J.H. Associations of P50 suppression and desensitization with perceptual and cognitive features of "unreality" in schizotypy. Biol. Psychiatry 50 6 (2001) 441-446
11. Cullum C.M., Harris J.G., Waldo M.C., Smeroff E., Madison A., Nagamoto H.T., Griffith J., Adler L.E., and Freedman R. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr. Res. 10 2 (1993) 131-141
12. Dones I. Intrathecal baclofen for the treatment of spasticity. Acta Neurochir. Suppl. 97 Pt 1 (2007) 185-188
13. Donohue M., Wei W., Wu J., Zawia N.H., Hyd N., De Jesus V., Schmechel D., Hettick J.M., Beezhold D.H., and Vesper S. Characterization of nigerlysin, hemolysin produced by Apergillus niger, and effect on mouse neuronal cells in vitro. Toxicol 219 1-3 (2006) 150-155
14. Erwin R.J., Turetsky B.I., Moberg P., Gur R.C., and Gur R.G. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr. Res. 33 3 (1998) 157-167
15. Essock S.M., Hargreaves W.A., Covell N.H., and Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol. Bull. 32 4 (1996) 683-697
16. Fleischhaker C., Schulz E., Tepper K., Martin M., Hennighausen K., and Remschmidt H. Long-term course of adolescent schizophrenia. Schizophr. Bull. 31 3 (2005) 769-780
17. Gardner I., Leeder J.S., Chin T., Zahid N., and Uetrecht J.P. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 53 6 (1998) 999-1008
18. Hasan N.Y., Elkawy M.A., Elzeany B.E., and Wagieh N.E. Stability indicating methods for the determination of clozapine. J. Pharm. Biomed. Anal. 30 1 (2002) 35-47
19. Hashimoto K., Iyo M., Freedman R., and Stegens K.E. Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of α7 nicotinic acetylcholine receptors. Psychopharmacol. 183 1 (2005) 13-19
20. Iqbal M.M., Rahman A., Husain Z., Mahmud S.Z., Ryan W.G., and Feldman J.M. Clozapine: a clinical review of adverse effects and management. Ann. Clin. Psychiatry 15 1 (2003) 33-48
21. Jang J., Yaksh T.L., and Hill H.F. Use of 2-hydroxypropyl-beta-cyclodextrin as an intrathecal drug vehicle with opioids. J. Pharmacol. Exp. Ther. 261 2 (1992) 592-600
22. Kapur S., Vanderspek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 2 (2003) 625-631
23. Koulousakis A., Kuchta J., Bayarassou A., and Sturm V. Intrathecal opioids for intractable pain syndromes. Acta Neurochir. Suppl. 97 pt 1 (2007) 43-48
24. Levy R. Implanted drug delivery systems for control of chronic pain. Chapter 19 of Neurosurgical Management of Pain (1997), Springer-Verlag, New York, NY
25. Light G.A., Geyer M.A., Clementz B.A., Cadenhead K.S., and Braff D.L. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry 157 5 (1993) 767-771
26. Lublin H., Eberhard J., and Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int. Clin. Psychopharmacol. 20 4 (2005) 183-198
27. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., and Hsiao J.K. CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 4 (2006) 600-610
28. Miller D.D. Review and management of clozapine side effects. J. Clin. Psychiatry 61 Suppl 8 (2000) 14-17
29. Miller C.L., and Freedman R. The activity of hippocampal interneurons and pyramidal cells during the response of the hippocampus to repeated auditory stimuli. Neurosci. 69 (1995) 371-381
30. Nagamoto H.T., Adler L.E., Hea R.A., Griffith J.M., McRae K.A., and Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol. Psychiatry 40 3 (1996) 181-188
31. Nagamoto H.T., Adler L.E., McRae K.A., Heuttl P., Cawthra E., Gerhardt G., Hea R., and Griffith J. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-hydroxyphenylglycol. Neuropsychobiology 39 1 (1999) 10-17
32. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., Ellis J., Zerbe G.O., Leonard S., Stevens K.E., Stevens J.O., Martin L., Adler L.E., Soti F., Kem W.R., and Freedman R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 63 6 (2006) 630-638
33. Overstreet D.H., Commissaris R.C., De La Garza R., File S.E., Knapp D.J., and Seiden L.S. Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence from genetic models. Stress 6 2 (2003) 101-110
34. Powell C.M., and Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol. Psychiatry 59 12 (2006) 1198-1207
35. Radek R.J., Miner H.M., Bratcher N.A., Decker M.W., Goplalakrishnan M., and Bitner R.S. Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating. Psychopharmacol. (Berl). 187 1 (2006) 47-55
36. Reid W.H., Mason M., and Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr. Serv. 49 8 (1998) 1029-1033
37. Richard I., and Menei P. Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders. Acta Neurochir. Suppl. 97 Pt 1 (2007) 213-218
38. Serralta A., Barcia J.A., Ortiz P., Duran C., Hernandez M.E., and Alos M. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model. Epilepsy Res. 70 1 (2006) 15-26
39. Shirazi-Southall S., Rodriguez D.E., and Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacol 26 5 (2002) 583-594
40. Simosky J.K., Stevens K.E., Adler L.E., and Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacol. 165 4 (2003) 386-396
41. Stevens K.E., Freedman R., Collins A.C., Hall M., Leonard S., Marks M.J., and Rose G.M. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neurospychopharmacol 15 2 (1996) 152-162
42. Stevens K.E., Kem W.R., Mahnir V.M., and Freedman R. Selective alpha-7 nicotinic agonists normalize inhibition of auditory response in DBA/2 mice. Psychopharmacol. 136 4 (1998) 320-327
43. Tauscher J., Hussain T., Agid O., Verhoeff N.P., Wilson A.A., Houle S., Remington G., Zipursky R.B., and Kapur S. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am. J. Psychiatry 161 9 (2004) 1620-1625
44. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., and Lieberman J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 159 2 (2002) 255-262
45. Yaksh T.L. Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol. Sci. 20 8 (1999) 329-337
46. Yaksh T.L., Jang J.D., Nishiuchi Y., Braun K.P., Ro S.G., and Goodman M. The utility of 2-hydroxypropyl-beta-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs. Life Sci. 48 7 (1991) 623-633